Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amanat Acquisition Corp.AMAN · Entity 6741 | Director · Chief Executive Officer | May 18, 2026 | May 19, 2026 |
| Retension Pharmaceuticals, Inc.RTSN · Entity 184313 | Director | October 13, 2026 | October 13, 2026 |
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Director · Chief Executive Officer | December 08, 2021 | December 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amanat Acquisition Corp.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person beneficially owns 150,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2: For his services as a director and Chief Executive Officer, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person beneficially owns 150,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.
F2: For his services as a director and Chief Executive Officer, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.
Retension Pharmaceuticals, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.63 · Expires 2036-10-13 | Direct | 5,636 |
Reported balance
After 2026-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-13 · Grant · Acquired 5,636 · Balance 5,636 F1: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Sio Gene Therapies Inc.
Report date December 08, 2021 · Filed December 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 203,109 |
Ending reported balance
After 2021-12-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-12-08 · Grant · Acquired 37,567 · Balance 217,993 Row 2 · 2021-12-08 · Tax withholding · Disposed 14,884 · Balance 203,109 F1: The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 75,133 |
Reported balance
After 2021-12-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-08 · Disposition to issuer · Disposed 37,567 · Balance 75,133 F2: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F3: 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
F2: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
F3: 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 13, 2026 22:11 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | GrantStock Option (right to buy) · Derivative | 5,636 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0001213900-26-109157 · ownership.xml · derivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,636 Underlying: Common Stock · 5,636 shares Expires 2036-10-13 F1 · security: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.exercise_date: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 23:31 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | Disposition to issuerRestricted Stock Units · Derivative | 37,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-21-000098 · wf-form4_163909265726806.xml · derivative · entry 3 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,133 Underlying: Common Stock · 37,567 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F3 · derivative.exercise_date: 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. F3 · derivative.expiration_date: 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 23:31 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | Tax withholdingCommon Stock | 14,884 | $1.42 | $21,135.28 |
DisclosureSEC source: 0001636050-21-000098 · wf-form4_163909265726806.xml · nonDerivative · entry 2 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,109 F1 · shares: The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 23:31 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantCommon Stock | 37,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-21-000098 · wf-form4_163909265726806.xml · nonDerivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,993 Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:51 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 682,100 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001636050-21-000044 · wf-form4_161886549794518.xml · derivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,100 Underlying: Common Stock · 682,100 shares Expires 2031-04-14 F1 · derivative.exercise_date: The option vests over a period of three years with one-third of the shares of common stock underlying the option vesting on April 15, 2022 and the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. Read SEC document |
| March 23, 2021 Filed Mar 24, 2021 23:21 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | PurchaseCommon Stock | 100,000 | $2.48 | $248,180.00 |
DisclosureSEC source: 0001636050-21-000033 · wf-form4_161662808813010.xml · nonDerivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,426 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50 per share, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:55 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | Disposition to issuerRestricted Stock Units · Derivative | 22,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-21-000027 · wf-form4_161618733299469.xml · derivative · entry 2 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,590 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on July 31, 2020 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:55 UTC | Sio Gene Therapies Inc. SIOX · Entity 130622 | GrantCommon Stock | 22,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-21-000027 · wf-form4_161618733299469.xml · nonDerivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,426 Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 22:11 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | PurchaseCommon Shares | 37,500 | $2.74 | $102,637.50 |
DisclosureSEC source: 0001209191-20-042215 · doc4.xml · nonDerivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,836 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person at $3.09 per share on June 11, 2020. The reporting person has paid to the Issuer the $3,616.37 loss avoided by the reporting person in connection with the short-swing transaction. F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.70 to $2.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:39 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | Disposition to issuerRestricted Stock Units · Derivative | 22,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036807 · doc4.xml · derivative · entry 3 Cheruvu Pavan · CIK 0001731741 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,590 Underlying: Common Shares · 22,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. F3 · derivative.exercise_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. F3 · derivative.expiration_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:39 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | Tax withholdingCommon Shares | 9,755 | $3.09 | $30,142.95 |
DisclosureSEC source: 0001209191-20-036807 · doc4.xml · nonDerivative · entry 2 Cheruvu Pavan · CIK 0001731741 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,336 F1 · shares: The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:39 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantCommon Shares | 22,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036807 · doc4.xml · nonDerivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,091 Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 00:59 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantRestricted Stock Units · Derivative | 112,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025015 · doc4.xml · derivative · entry 2 Cheruvu Pavan · CIK 0001731741 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,700 Underlying: Common Shares · 112,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third of the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. F3 · derivative.expiration_date: One-third of the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 00:59 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 169,100 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001209191-20-025015 · doc4.xml · derivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,100 Underlying: Common Shares · 169,100 shares Expires 2030-04-14 F1 · derivative.exercise_date: The option vests over a period of four years with 25% of the common shares underlying the option vesting on April 15, 2021 and the remainder vesting in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| September 21, 2019 Filed Sep 24, 2019 21:14 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantRestricted Stock Units · Derivative | 45,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001636050-19-000084 · wf-form4_156935967895760.xml · derivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Principal Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,181 Underlying: Common Shares · 45,181 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. F2 · derivative.expiration_date: 50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 23:09 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | PurchaseCommon Stock | 7,500 | $5.21 | $39,075.00 |
DisclosureSEC source: 0001209191-19-037525 · doc4.xml · nonDerivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9798 to $5.35 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 01:14 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option ( Right to Buy) · Derivative | 1,596,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025189 · doc4.xml · derivative · entry 2 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,000 Underlying: Common Stock · 1,596,000 shares Expires 2029-04-14 F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F3 · derivative.exercise_date: One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $2.12; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $4.24; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $6.36, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 01:14 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option ( Right to Buy) · Derivative | 1,596,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025189 · doc4.xml · derivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,000 Underlying: Common Stock · 1,596,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: The option vests over a period of four years, with one quarter of the common shares underlying the option vesting on April 15, 2020 and the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. F2 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:43 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,940,185 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-18-010478 · doc4.xml · derivative · entry 1 Cheruvu Pavan · CIK 0001731741 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,940,185 Underlying: Common Shares · 1,940,185 shares Expires 2028-02-12 F1 · derivative.exercise_date: 25% of the common shares underlying the option will vest on February 11, 2019; the remainder vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.